Financial News

Moberg Pharma Sells OTC Business

Author Image

By: TOM BRANNA

Editor

Moberg Pharma, Stockholm, has entered into an agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest its entire OTC operation—which includes topical treatments like Kerasal Nail, Dermoplast and New Skin—in deal that includes a cash consideration of $155 million plus an additional consideration of $5 million.

In the most recent fiscal year, Kerasal Nail recorded its third consecutive year of double-digit growth in the US and in 2018 became ranked as the No. 1 individual product in the nail fungus segment as well as in the entire foot care category, according to Moberg.

According to Moberg, the OTC-business generated sales of approximately $46.7 million in 2018.

The sale of the OTC unit will provide funding for development and commercialization of a product in Moberg’s pipeline called MOB-015, which the firm also announced it will commercialize with Bayer AG through a licensing deal.

RoundTable Healthcare Partners’ portfolio includes physician-dispensed Revision Skincare and Goodier Cosmetics, injectables and more.

Keep Up With Our Content. Subscribe To Happi Newsletters